Phase 3 Trial of Carboplatin in Triple Negative Breast Cancer Patient with Residual Invasive Carcinoma After Neoadjuvant Chemotherapy(Transitioned to jRCT)

Phase 3 Trial of Carboplatin in Triple Negative Breast Cancer Patient with Residual Invasive Carcinoma After Neoadjuvant Chemotherapy(Transitioned to jRCT) - P3 Trial of Cb on non pCR TNBC

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030780

Enrollment

270

Registered

2018-03-01

Start date

2018-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Triple Negative Breast Cancer

Interventions

Observation Carboplatin AUC6 q3wks x4

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: (1) Triple negative breast cancer patients i) ER and PgR negative (IHC<10 %) ii) HER2 negative (IHC 1+/0 or IHC 2+/FISH-) (2) Patients who received Anthracycrine and Taxan treatment preoperatively. (3) Patients with residual invasive cancer or lymph node metastasis on surgical specimens (4) Within 3 months after surgery (5) Written consent

Exclusion criteria

Exclusion criteria: (1) previously treated with Carboplatin (2) other cancer (3) bilateral breast cancer (4) during pregnancy or breast feeding (5) attended clinical trial within 6 month (6) metastatic breast cancer (7) heavy disorder of heat, kidney or liver (8) doctor's dicision of inadequacy

Design outcomes

Primary

Measure	Time frame
3 years of disease free survival	—

Secondary

Measure	Time frame
Safety, 5 years of over all survival	—

Countries

Japan

Contacts

Public ContactHirokazu Tanino MD, PhD

Kobe University Hospital Department of Breast Surgery

htanino@med.kobe-u.ac.jp078-382-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026